Pregabalin 150mg BID

DRUG2 trials

Sponsors

Haisco Pharmaceutical Group Co., Ltd.

Conditions

Diabetic Peripheral Neuropathic Pain

Phase 2

To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain

Haisco Pharmaceutical Group Co., Ltd.Diabetic Peripheral Neuropathic Pain

Start: 2020-12-02End: 2022-11-16Target: 687Updated: 2020-12-01

Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had an Inadequate Response to Pregabalin

RecruitingNCT06490484

Haisco Pharmaceutical Group Co., Ltd.Diabetic Peripheral Neuropathic Pain

Start: 2024-04-19End: 2024-07-14Target: 90Updated: 2024-07-08

Related Papers

1432-P: Enhanced Efficacy of Crisugabalin 80 mg/day in Diabetic Peripheral Neuropathic Pain Patients with BMI ≥25 kg/m² or Longer Disease Duration: A Post Hoc Analysis

Diabetes2026-06-05

Rapid Onset of Pain Relief with Crisugabalin in Patients with Diabetic Peripheral Neuropathic Pain: Findings from a Multicenter, Randomized, Double-Blind, Controlled Study

Pain and Therapy2025-05-161 citations

Efficacy and Safety of Crisugabalin (HSK16149) in Adults with Postherpetic Neuralgia

JAMA Dermatology2024-09-2514 citations

GABA Analogue HSK16149 in Chinese Patients With Diabetic Peripheral Neuropathic Pain

JAMA Network Open2024-08-1913 citations